Real-World Evidence of Temporal Variation in PD-L1 Expression

被引：0
|
作者：
Sudarsanam, Sucha [1 ]
Hatooglu, Medina [1 ]
O'Malley, Dennis [2 ]
Weiss, Lawrence [3 ]
机构：
[1] NeoGen Labs Inc, Aliso Viejo, CA USA
[2] NeoGen Labs Inc, Dana Point, CA USA
[3] NeoGen Labs Inc, Pasadena, CA USA
来源：
MODERN PATHOLOGY | 2020年 / 33卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1830
引用
收藏
页码：1713 / 1714
页数：2
相关论文
共 50 条
  • [41] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [42] PD-L1 expression of medulloblastoma
    Cakmak, P.
    Kolay, E.
    Poyraz, A.
    VIRCHOWS ARCHIV, 2018, 473 : S28 - S28
  • [43] PD-L1 Expression in Mastocytosis
    Williams, Margaret
    Lidke, Diane S.
    Hartmann, Karin
    George, Tracy I.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [44] PD-L1 Expression in Sarcomas
    Kosemehmetoglu, Kemal
    Ozogul, Ece
    Babaoglu, Berrin Buyukeren
    Tezel, Gaye Y. Guler
    Gedikoglu, Gokhan M.
    MODERN PATHOLOGY, 2017, 30 : 18A - 18A
  • [45] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [46] PD-L1: expression regulation
    Zhou, Yu-Jie
    Li, Guoli
    Wang, Jiyin
    Liu, Mengyuan
    Wang, Zihan
    Song, Yu
    Zhang, Xulong
    Wang, Xi
    BLOOD SCIENCE, 2023, 5 (02): : 77 - 91
  • [47] Expression of PD-L1 in mastocytosis
    Kuklinski, Lawrence F.
    Kim, Jinah
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : 1010 - 1012
  • [48] Real-world PD-L1 test utilization and analytical concordance of the PD-L1 IHC 28-8 and 22C3 assays in patients with breast cancer
    Mitra, Shreya
    Prince, Emily A.
    Pratt, James
    Novotny, James, Jr.
    Chizhevsky, Vladislav
    Ragheb, Josette William
    Huron, David
    CANCER RESEARCH, 2021, 81 (04)
  • [49] REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC A Multicenter Cohort Study in Argentina
    Picon, C. R.
    Rizzo, M. M.
    Sanchez del Cid, M.
    Amorin, R.
    Tsou, F.
    Castro, N.
    Garcia, M. B.
    Cheng, S.
    Scocimarro, A.
    Rapaccioli, M.
    Castagneris, N.
    Malcervelli, G.
    Levit, P.
    Carranza, O.
    Piazzoni, L.
    Kaen, D.
    Ayala, N.
    Martin, C.
    Lupinacci, L.
    Puparelli, C.
    Basbus, L.
    Enrico, D.
    Garcia Giner, B.
    Perfetti, A.
    Vera, K.
    Bluthgen, V.
    Sena, S.
    Riso, A.
    Gayet Preiss, F.
    Kowalyszyn, R.
    Barbaro, F.
    Santa Cruz, M. A.
    Bastida, N.
    Minatta, J. N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S605 - S606
  • [50] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
    Julian, C.
    Machado, R.
    Girish, S.
    Chanu, P.
    Heinzmann, D.
    Harbron, C.
    Gershon, A.
    Pfeiffer, S.
    Zou, W.
    Quarmby, V.
    Zhang, Q.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
12345